On July 29, 2016, the FDA announced approval of the CyPass^® Micro-Stent, a micro invasive glaucoma surgical (MIGS) device manufactured by Alcon (a division of Novartis) to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery.

As the FDA explained, the CyPass® Micro-Stent is a tiny tube that is implanted into the eye during cataract surgery to help drain fluid that builds up in patients with glaucoma. The CyPass® Micro-Stent is designed to control eye pressure (intraocular pressure, or IOP) by creating a drainage pathway from the inside (anterior chamber) to the outermost layer of the eye (suprachoroidal space).

The CyPass® Micro-Stent is used in patients with primary open angle glaucoma (POAG). If not treated, pressure builds up inside the eye and eventually can damage the optic nerve, causing blindness.

Click here ^[1] to read the full FDA announcement.

Click here to learn more about the CyPass Micro-Stent ^[2].